U.K. CRO Chiltern has wrapped up its acquisition of former U.S. competitor Theorem Clinical Research, expanding its payroll and global reach in the process.
PRA Health Sciences is building up its presence in Pennsylvania, adding 150 jobs with plans to dial up recruitment over the next two years.
CRO Accelovance is teaming up with a cancer-focused nonprofit to broaden its services in oncology trials, widening its net of expert investigators.
AMRI is brightening its expectations for 2015 after closing its latest buyout, counting on its manufacturing division to keep revenue rolling.
WuXi PharmaTech, making use of its recent $65 million investment in genomics, is teaming up with a Shanghai hospital to expand the scope of precision medicine in its home country.
German research outfit Evotec is dialing up its full-year revenue expectations thanks to a series of contract wins.
CRO Aragen Biosciences signed a deal with Dutch service provider ProteoNic Biotechnology to get its hands on a protein-production technology it believes can improve biologics development.
Private CRO Rho inked its largest-ever federal contract, signing a 7-year deal with the U.S. National Institutes of Health that will pay out about $16.5 million each year.
Hybrid R&D outfit Evotec signed a deal with Pfizer to collaborate on tissue fibrosis research, lending its expertise and discovery technology to the pharma giant in exchange for a cut of the benefits.
Swedish contract drugmaker Recipharm signed a deal with neighboring LobSor Pharmaceuticals to manufacture the company's new treatment for Parkinson's disease, all the while discussing a partnership with Novartis in the field of eye care.
CRO giant Icon is working with IBM in hopes of making clinical trials more efficient, tapping the company's famed Watson technology with an eye on speeding up recruitment and site selection.
Catalent watched as some unfavorable currency trends sapped its fiscal year revenue growth, but the company closed out its transformational year with a major increase in profits that management said is a sign of things to come.
The U.K.'s National Health Service has approved the use of inVentiv Health's informed consent technology, another victory for the CRO's pioneering software.
PPD has reached out to clinical trial software provider Cisys LifeSciences to get its hands on technology the company believes can improve the process by which investigators examine and adjudicate safety events.
WuXi PharmaTech's small-molecule business won approval to produce drugs in Japan, extending the CRO's reach as it looks to beef up its manufacturing revenue.
China's Shenzhen Hepalink Pharmaceutical signed a deal to acquire contract drugmaker Cytovance Biologics for $205.7 million in cash, buying into the U.S.'s burgeoning market for large-molecule treatments.
Clinical trial technology outfit BioClinica has created what it's calling an app exchange, looking for new software that can help physicians and drug developers through the company's cloud-based data service.
Contract drugmaker AMRI signed a deal with Italy's Saneca Pharmaceuticals to collaborate on opium-derived treatments, pairing up with eyes on the U.S. market for controlled substances.
Leading CRO INC Research is boosting its upper echelon in the areas of general medicine and central nervous system R&D, promoting two key members.
Chinese small-cap Lee's Pharm has signed CRO WuXi PharmaTech as its exclusive lab testing service to bolster the company's R&D program.